Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg 'continuing to bet' on Entain's BetMGM turnaround

(Sharecast News) - Analysts at Berenberg slightly raised their target price on bookmaker Entain from 1,010.0p to 1,035.0p on Tuesday, stating it was "continuing to bet" on the BetMGM turnaround. Berenberg said Entain was "a top pick" in the leisure space, with the group's recent update from its BetMGM joint venture on 4 February further reaffirming its positive view on the company.

"The US business has turned a corner, stabilising its market share and reaffirming its longer-term guidance of $500.0m of EBITDA," noted Berenberg. "Additional disclosure provided in this update leaves us impressed with the FY24 performance and confident for the year ahead."

The German bank, which has a 'buy' rating on the stock, continues to think that the BetMGM business has been undervalued in Entain's current share price, which it reckons should drive a re-rating this year as the market grows in confidence in BetMGM's outlook.

"We value Entain using a SOTP model and include a value for the BetMGM joint venture. This yields a value per share of 1,035.0p comprised of 620.0p for the ex-US business and 415.0p for the US business. On multiples, Entain trades on 19.4x FY25 EPS estimates, but this falls rapidly to sub-12x in FY26 as both the ex-US and US businesses deliver strong EBITDA growth," concluded Berenberg.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.